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Transporta b s t r a c t
Liposomal ciproﬂoxacin formulations have been developed with the aim of enhancing lung residence
time, thereby reducing the burden of inhaled antimicrobial therapy which requires multiple daily admin-
istration due to rapid absorptive clearance of antibiotics from the lungs. However, there is a lack of a pre-
dictive methodology available to assess controlled release inhalation delivery systems and their effect on
drug disposition. In this study, three ciproﬂoxacin formulations were evaluated: a liposomal formulation,
a solution formulation and a 1:1 combination of the two (mixture formulation). Different methodologies
were utilised to study the release proﬁles of ciproﬂoxacin from these formulations: (i) membrane diffu-
sion, (ii) air interface Calu-3 cells and (iii) isolated perfused rat lungs. The data from these models were
compared to the performance of the formulations in vivo. The solution formulation provided the highest
rate of absorptive transport followed by the mixture formulation, with the liposomal formulation provid-
ing substantially slower drug release. The rank order of drug release/transport from the different formu-
lations was consistent across the in vitro andex vivo methods, and this was predictive of the proﬁles
in vivo. The use of complimentary in vitro and ex vivomethodologies provided a robust analysis of formu-
lation behaviour, including mechanistic insights, and predicted in vivo pharmacokinetics.
 2013 Elsevier B.V. All rights reserved.1. Introduction
Respiratory administration is a well-established approach for
targeting drug delivery to treat respiratory diseases and offers
many advantages over other routes of administration. The direct
application of drugs into the respiratory tract provides rapid onset
of action, lower systemic exposure and subsequently reduced side
effects [1]. Hence, it is not surprising that inhalation antibiotics
have become a standard part of treatment for cystic ﬁbrosis (CF),
where recurrent pulmonary infection, especially with Pseudomonas
aeruginosa, is the main cause of morbidity and mortality [2,3].
While nebulised antibiotics such as tobramycin (TOBI) and aztre-
onam (Cayston) have proven to be an effective therapy against
respiratory tract infections in CF patients, these locally acting treat-
ments are rapidly cleared from the lungs. To maintain sufﬁciently
high levels of antibiotics for antimicrobial efﬁcacy, multiple dosesof high concentration antibiotics with lengthy administration
times are required each day.
A sustained release liposomal ciproﬂoxacin formulation was
developed recently with the aim of reducing the burden of therapy
by prolonging the residence time of drug in the lungs to reduce the
necessity for frequent administration. Additional potential beneﬁts
include improved antimicrobial efﬁcacy by maintaining high antibi-
otic levels throughout the dosing interval, decreasing systemic tox-
icity and improving local tolerability by avoiding excessive peak
concentrations of antibiotics in the airways [4–7]. The liposomal for-
mulation is a liquid nanosuspension of ciproﬂoxacin formulated
with lipids and cholesterol and delivered via nebulisation. Currently,
there is no regulatory approved aerosolised form of ciproﬂoxacin for
human use. Chronic use of oral and parenteral ciproﬂoxacin is lim-
ited by its systemic toxicity and by concerns over the emergence of
ciproﬂoxacin resistance in the community. Thus, inhaled liposomal
ciproﬂoxacin is an ideal candidate for chronic prophylactic manage-
ment of recurrent respiratory infections as it has an established
broad-spectrum activity and may be effective in preventing pul-
monary exacerbations associated with respiratory tract infections,
especially those caused by P. aeruginosa.
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trolled release products for inhalation, to date, there are no such
treatments on the market. The lack of standardised methodology
available to predict drug transport from potential controlled re-
lease inhalation delivery systems may, in part, have contributed
to the absence of such formulations, be it in the form of dry pow-
ders, pressurised metered dose inhalers or nebulised formulations
[8,9]. The disposition of drugs delivered to the lung is a complex
phenomenon that depends on the deposition pattern of the drug
formulation and the impact of the various mechanisms of distribu-
tion and elimination (release, absorption, phagocytosis, metabo-
lism, mucociliary clearance) [10,11]. In the past, drug transport
from experimental formulations has been investigated using one
of a multitude of methods, which are based on different principles
and assumptions [12]. This makes comparison between the differ-
ent controlled release formulations challenging and predictions of
behaviour in humans unreliable because none of the in vitrometh-
ods mimic fully the disposition mechanisms.
Further, non-primate animals have different anatomies and
physiologies of the respiratory tract compared to humans. Disease
condition can, of course, add another important dimension that is
difﬁcult, if not impossible, to simulate in in vitro, or even in animal,
models. Nevertheless, reductionist approaches can provide insights
into the mechanisms of release and absorption that may be partic-
ularly useful in early product development and mitigate certain
risks prior to investigations in humans. Drug release from pulmon-
ary dispersed systems, such as liposomes, is often evaluated using
simpliﬁed models [13–15]. A typical example is the membrane dif-
fusion method in which the carrier-dispersed phase is suspended
in a small volume of continuous phase, separated from a large sink
phase by a dialysis membrane that is permeable to the drug. This
apparatus is clearly not consistent anatomically with the in vivo
physiology encountered by inhaled dosage forms. Normal airways
are lined with approximately 1 lL per cm of liquid, consisting
predominantly of water, endogenous phospholipids and mucus
[16]. In addition, the normal mucosal airway pH is slightly acidic
(pH 6.6) compared to the blood which has a pH of 7.4 [17].
The characteristics of drug release from dispersed systems are
strongly inﬂuenced by the biological environment whereby inter-
actions of particles with biological components, such as phospho-
lipids and protein, could signiﬁcantly alter the release rate of the
drug. Therefore, in vitro models of the airway epithelium are being
utilised as representative models of the lungs for studying the im-
pact of formulation on respiratory release proﬁles [18–20]. In such
studies, air interfaced airway epithelial cells, such as Calu-3 cells
[18,21], are typically used to model the respiratory mucosal sur-
face, and a device for delivering a pharmaceutically-relevant aero-
sol, such as the twin stage impinger, is used to administer the
formulation. However, cell culture systems do not possess the in-
tact structure, the full absorptive pathway or the full spectrum of
inﬂuences on drug disposition that are present in the human lungs.
To study the kinetics of drug transport in the intact target organ, an
isolated perfused lung (IPL) model can be used [21]. The IPL is an
ex vivo model which possesses the structural integrity and func-
tionality of the lung tissue and, in comparison with in vivo meth-
ods, allows the investigation of drug absorption from the lungs
without the confounding contributions of oral systemic absorption,
distribution and elimination. Consequently, it allows the research-
er to elucidate the release kinetics of encapsulated drug and subse-
quent absorption resulting from the interaction of particles with
the pulmonary environment [22].
The aim of the current study was to investigate the impact of a
liposomal ciproﬂoxacin controlled release formulation on drug
transport in the lungs using complimentary in vitro techniques
and an ex vivo IPL model. The results were analysed with reference
to in vivo studies performed in mice using the same formulation[23]. This provides a rare illustration of the combined ability of
the non-clinical model systems to predict and explain the absorp-
tion proﬁles of a sustained release formulation from the lungs. The
kinetic proﬁles of the liposomal ciproﬂoxacin formulation are com-
pared to ciproﬂoxacin solution formulation across a series of
in vitro, ex vivo and in vivo methodologies, and the correlation
and advantages/disadvantages of each are appraised.2. Materials and methods
2.1. Materials
Calu-3 cells were purchased from the American Type Cell
Culture Collection (ATCC, Rockville, US). Nonessential amino acids
solution, trypan blue solution (0.4% w/v) and CelLytic™ M Cell
Lysis, protease inhibitor cocktail, were purchased from Sigma–
Aldrich (Sydney, Australia). Other cell culture reagents including
trypsin–EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA), Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM, without phenol red and
L-glutamine, including sodium bicarbonate and 15 mM HEPES),
Phosphate buffered saline (PBS), L-glutamine solution (200 mM),
foetal bovine serum (FBS) and Hank’s balanced salt solution (HBSS)
were obtained from Invitrogen (Sydney, Australia). Transwell cell
culture inserts (0.33 cm2 polyester, 0.4 lm pore size) were pur-
chased from Corning Costar (Lowell, MA, USA), and all other sterile
culture plastic wares were from Sarstedt (Adelaide, Australia). Salts
including NaCl, KCl, CaCl2, MgSO4, NaHCO3, KH2PO4, D-glucose,
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and
heparin were purchased from Sigma–Aldrich (Poole, UK). All sol-
vents used were of analytical grade and were supplied by Biolab
(Victoria, Australia).
2.2. Preparation of liposomal and solution ciproﬂoxacin formulations
The preparation of the ciproﬂoxacin formulations have been re-
ported previously [20]. Brieﬂy, liposomal ciproﬂoxacin, 50 mg/mL,
is an aqueous liposome formulation comprised of lipids and cho-
lesterol. It was prepared by an active loading method through a
transmembrane pH gradient, generated in response to an ammo-
nium sulphate gradient [23,24]. Free ciproﬂoxacin, 20 mg/mL, is
an acetate-buffered aqueous formulation at pH 3.3. To produce
the mixture formulation, equal concentrations of the liposomal
and solution formulations were added together immediately prior
to the experiments to produce a concentration of 50:50 (% w/w).
2.3. Ciproﬂoxacin analysis
The HPLC system used to measure ciproﬂoxacin concentrations
in the isolated perfused lung samples consisted of a SpectraSYS-
TEM UV1000 UV–vis detector (Thermoseparation Products, Sal-
ford, UK), JASCO PU-980 HPLC pump (Jasco, Tokyo, Japan),
SpectraSYSTEM AS3000 Autosampler (Thermoseparation Products,
Salford, UK) and an Optimal ODS-H column (3 lm, 150  4.6 mm,
Capital HPLC Limited, Broxburn, West Lothian, Scotland). The mo-
bile phase was a mixture of methanol and 0.1 M sodium dihydro-
gen phosphate, at a 30:70 (% v/v) ratio, with pH adjusted to 3.35
with phosphoric acid. The ﬂow rate was set to 0.8 mL/min, and
50 lL of each sample was injected into the column. The UV detec-
tor was set to 275 nm. Linearity of ciproﬂoxacin was obtained be-
tween 0.1 and 50 lg/mL (R2 = 0.99), with a retention time of
14.6 min.
Quantitation of ciproﬂoxacin for samples from all other experi-
ments was performed using the HPLC method as previously
described [18,20]. To determine the total ciproﬂoxacin concentra-
tion, the liposomal and mixture formulation samples required
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separate the drug from the lipids. This was accomplished by dilu-
tion with methanol to a concentration of 80:20 (% v/v) metha-
nol:water. The samples were then centrifuged at 10,000g for
5 min to allow sedimentation of the lipids. The supernatant was
collected and further diluted 10 with deionised water, prior to
quantiﬁcation by high-performance liquid chromatography
(HPLC).
2.4. Dialysis membrane diffusion
Dialysis membranes (MW cut-off 6000–8000, Cellu.Sep, Texas,
USA) were soaked in deionised water for 20 min prior to use to en-
sure thorough wetting of the membrane. The pore size of the dial-
ysis bag was chosen to allow free diffusion of ciproﬂoxacin into the
sink phase and to prevent the exit of the liposomal nanoparticles.
This study was carried out in phosphate buffered saline (PBS) at
pH 7.4 over the same 240 min period of time used for the invitro
cell model studies. The liposomal and mixture formulations
(1 mL) were enclosed in the dialysis bag, which was immersed in
200 mL of PBS solution to ensure sink conditions. The solutions
were maintained at 37 C in a water bath under constant agitation
using a magnetic stirrer (300 rpm). Samples of 600 lL were with-
drawn at pre-determined time points (5, 10, 15, 30, 120, 150,
180 and 240 min) from the incubation medium and were replaced
with equal volumes of fresh phosphate buffer solutions (PBS). Con-
trol experiments were also performed to determine the release
behaviour of the drug from the solution formulation using the
same procedure. All experiments were performed in triplicate.
2.5. Absorptive proﬁling in vitro
Calu-3 cells were grown at the air interface, as described previ-
ously [20,25]. Experiments were performed between day 11 and
14, from passages 35–42. Deposition of aerosolised formulations
onto the Calu-3 cells was performed using a modiﬁed glass twin
stage impinger apparatus (TSI; British Pharmacopoeia Apparatus
A, Copley Scientiﬁc, UK) that accommodates a transwell insert lo-
cated at the end of the jet in the second lower chamber (absence
of solution). The set-up of the apparatus is described in detail else-
where [18,26]. The PARI LC Sprint nebuliser, powered by the PARI
TurboBoyS compressor, was ﬁtted to the entrance of the TSI using
a custom-made mouthpiece adapter, and the experimental method
followed that of Ong et al. [20]. Brieﬂy, 2 mL of the mixture formu-
lation (2.5 mg/mL) was nebulised for 5 s at a ﬂow rate of 15 L/min
to allow <20 lg of ciproﬂoxacin to be deposited onto the Calu-3
cells during the formulation.
Immediately after deposition, the Transwell insert was re-
moved, the outer surface was wiped dry to remove any external
adhering droplets, and the insert was placed into a well of a 24-
well plate containing 600 lL of pre-warmed HBSS (receiver ﬂuid).
Samples were transferred to a new well containing fresh HBSS at
pre-determined time points (up to 4 h) to maintain sink conditions.
At the ﬁnal time point, cells were gently washed with HBSS to col-
lect the remaining drug on the cell surface and subsequently har-
vested and lysed on ice in CellLytic™ M Cell Lysis reagent with
1% (v/v) protease inhibitor cocktail, according to manufacturer’s
recommendation to quantify intracellular drug. Lysates were cen-
trifuged at 10,000g for 10 min at 4 C. The supernatant was then
aspirated and diluted to an appropriate volume. Samples were ana-
lysed by HPLC. The sum of the drug that was transported across the
epithelial cells and the drug recovered from the surface and ‘inside’
the cells after the 4 h period provided an estimate of the quantity
of ciproﬂoxacin deposited on the cells.
Assessment of the Calu-3 monolayer’s integrity was performed
using transepithelial electrical resistance (TEER) measurements, aspreviously described [18,27], using an epithelial voltohmmeter
(EVOM, World Precision Instruments, USA). TEER measurements
were performed on untreated-control cells and after the deposition
experiments were complete.
2.6. Isolated perfused lung
Lungs were obtained from male Wistar rats weighing 220–
300 g (Harlan UK Ltd., UK). Rats were anesthetised by intraperito-
neal injection of pentobarbitone (1.2 mL/kg of a 200 mg/mL solu-
tion). The lungs were excised and perfused through the
pulmonary artery on the basis of a method previously described
[28]. Brieﬂy, after the tracheal intubation, the lung was inﬂated
with 1.5 mL air. The abdomen was opened and heparin (500 inter-
national units [IU], Leo Ltd., UK) injected into the vena cava. The
animals were then exsanguinated by withdrawal of blood from
the inferior vena cava, and the thorax was opened. A cannula
was inserted into the pulmonary artery and held in place by tight-
ening a ligature previously placed around the pulmonary artery
and aorta. The lower parts of the ventricles were cut to allow free
efﬂux of the perfusate. Perfusion, in a single pass mode, was com-
menced with modiﬁed Krebs buffer (composition mmol/L: NaCl
118 mM, KCl 4.7 mM, CaCl2 2.5 mM, MgSO4 1.2 mM, NaHCO3
24.9 mM, KH2PO4 1.2 mM, HEPES 10 mM, D-glucose 11 mM). The
lungs, heart and trachea were then removed and suspended over
a beaker at room temperature during the drug absorption study.
Krebs buffer was held in a heated (37 C) reservoir and saturated
with 95% oxygen: 5% carbon dioxide mixture and the perfusion
ﬂow rate were maintained at ca. 8 mL/min using a peristaltic pump
(Masterﬂex, UK). The efﬂuent perfusate was collected, and 5 mL
aliquots were removed at different time points.
2.7. Absorptive proﬁling ex vivo
After isolation, the lung preparation was allowed to stabilise for
2–3 min before delivery of the formulations. The formulations
were diluted with PBS solution to a ciproﬂoxacin concentration of
5 mg/mL. A volume of 100 lL of each diluted formulation was in-
stilled into the lungs (equivalent to 500 lg of ciproﬂoxacin)
through the tracheal cannula using a 10 mL syringe and chased by
approximately 2 mL of air to distribute the solution and re-inﬂate
the lungs. Air volume in the lungswas kept constant; perfusion ﬂow
was stable throughout the experiment and was not inﬂuenced by
drug administration. This method of administration provides pre-
cise control of the dose, minimising drug loss in the instrumenta-
tion and bypassing nasal and oropharyngeal deposition. Perfusion
buffer that dripped from the left atrium was sampled at pre-
determined time points (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20
and 25 min). The tissue viability was veriﬁed by visual inspection
and for signs of oedema and by determination of the wet to dry
weight ratios after incubation of the lung at 80 C for 24 h.
Samples collected were treated by diluting with equal volumes
of methanol. Subsequently, the samples were vortexed and centri-
fuged at 13,000 rpm for 20 min. The supernatant was collected for
quantiﬁcation of ciproﬂoxacin by HPLC analysis. For the liposomal
and mixture formulations, 2 mL of samples was left to dry over-
night. The samples were then rinsed with 0.4 mL for the liposomal
formulation or 1 mL for the mixture formulation, using 50:50 (% v/
v) methanol:water. This was performed to increase the drug con-
centration in the samples for quantiﬁcation.
2.8. Data analysis
The drug mass transport (% absorbed) from the airways to the
perfusate during the 30 min IPL experiments was calculated as
the mass fraction of the given dose recovered from the perfusate.
Fig. 2. Cumulative absorptive ciproﬂoxacin transport after deposition of aeroso-
lised solution, mixture and liposomal formulations to the surface of air interface
cultured Calu-3 epithelial cell layers (nP 3, mean ± SD).
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ments on the air interface Calu-3 cell model, whereby the drug
mass transport from the Calu-3 was calculated as the cumulative
mass fraction of the total drug recovered throughout the 4 h exper-
iment as previously described [18]. For the dialysis membrane dif-
fusion experiment, drug concentrations were measured and
expressed in terms of per cent total recovery. All data were subse-
quently plotted as mean cumulative percentages (±standard devi-
ation) of drug release/transport versus time.
The ciproﬂoxacin kinetics from the different methodologies
were ﬁtted to mathematical models that describe drug dissolution
and diffusion functions, speciﬁcally Zero order, First order, Higuchi
and Hixon–Crowell. The linearised forms of these functions were
evaluated using R2 regression analysis. Of course, it must be appre-
ciated that a good numerical ﬁt is not necessarily a conﬁrmation of
a speciﬁc physical mechanism and that the goodness of ﬁt depends
on the extent of release observed [29].
3. Results
3.1. Dialysis membrane diffusion
The release proﬁle of each formulation across a dialysis mem-
brane was studied in PBS at pH 7.4 and 37 C. Over the 4 h exper-
iment, the solution formulation demonstrated rapid ciproﬂoxacin
diffusion from the dialysis bag with >96% of the drug released
(Fig. 1), suggesting no retardation of drug diffusion across the dial-
ysis membrane. The release proﬁles from the liposomal and mix-
ture formulations suggested sustained release of ciproﬂoxacin.
The release over the 4 h period was approximately 8% and 33% of
ciproﬂoxacin from the liposomal and mixture formulations,
respectively.
3.2. Absorptive proﬁling in vitro
The total amount of ciproﬂoxacin deposited onto the Calu-3
cells from the three formulations was equivalent (11.14 ±
3.47 lg, p > 0.05). However, each formulation displayed different
kinetic proﬁles (Fig. 2). The liposomal ciproﬂoxacin formulation
presented a sustained release proﬁle of antibiotic, with only 1.5%
of the drug being transported across the epithelia over a 4 h period.
In comparison, the solution formulation delivered a more rapid
transport rate of ciproﬂoxacin with >33% of the drug being
absorbed across the cells. The mixture formulation showed an
intermediate transport rate, with approximately 7% of the drug
being transported across the Calu-3.
The deposition of the nebulised formulations on the epithelial
cells using the modiﬁed TSI did not produce a detrimental effectFig. 1. In vitro drug release proﬁles of ciproﬂoxacin across a dialysis membrane
from the ciproﬂoxacin solution (SD < 5%), mixture formulation (SD < 1.1%) and
liposomal ciproﬂoxacin (SD < 1.5%) (n = 3, mean ± SD).on the integrity of the cells under the conditions and timescale
studied, as measured by transepithelial electrical resistance which
remained unchanged from the control at 548 ± 3X cm2 (n = 3,
p > 0.05).
3.3. Isolated perfused lung model
Discrete absorptive proﬁles of drug into the perfusate were
measured from each of the ciproﬂoxacin formulations (Fig. 3). Over
25 min, 82 ± 5.5% of the delivered dose of the free ciproﬂoxacin for-
mulation was transported into the perfusate. In comparison, the
liposomal formulation resulted in a slower drug transport, with
the cumulative amount of ciproﬂoxacin transported being
12.3 ± 1.8%. Administration of the mixture formulation resulted
in 33.1 ± 4.3% of the ciproﬂoxacin being transported into the per-
fusate in 25 min, presumably reﬂecting principally the rapid
absorptive clearance of the free ciproﬂoxacin component. No lung
oedema was present during any of the experiments; determined
visually or by weight.
3.4. Release kinetics of ciproﬂoxacin from nebuliser formulations
Distinct kinetic proﬁles from the liposomal and solution formu-
lations were obtained across all methodologies. The kinetics of the
solution formulation were dependent on concentration (i.e. the
rate of transport/diffusion decreased as time increased). In com-
parison, the liposomal formulation demonstrated an approxi-
mately linear proﬁle with time. The proﬁles obtained for the
mixture formulation varied according to the methodologies,
suggesting that a method-dependent impact on the observed
transport rates. Conventional, mathematical models of drugFig. 3. Cumulative percentage of ciproﬂoxacin transferred to the perfusate vs. time
in the isolated perfused rat lung model following intratracheal administration of
100 lL of ciproﬂoxacin 5 mg/mL formulations (n = 4, mean ± SD).
Table 1
The absorptive half-life of ciproﬂoxacin delivered in the liposomal and solution formulations, estimated using the best-ﬁt mathematical model.
Best-ﬁt model Half-life, t½ (min)
Calu-3 Dialysis bag Isolated perfused lung (IPL) In vivo mice lunga
Free ciproﬂoxacin (FCI) Higuchi 723 ± 319 (R2 = 0.964) 39 ± 28 (R2 = 0.84) 12.7 ± 2.1 (R2 = 0.990) 7.8b
Liposomal ciproﬂoxacin (CFI) Zero order 16031 ± 11,549 (R2 = 0.872) 2255 ± 422 (R2 = 0.982) 99.2 ± 15.3 (R2 = 0.996) 697 (R2 = 0.982)
a From Ref. Yim et al. [23].
b Estimated from the ﬁrst two points of the free ciproﬂoxacin data as >95% of the drug has been transported across the lungs within the ﬁrst 15 min (Fig. 4).
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ﬁt mathematical function was selected based on the correlation
coefﬁcient criterion, R2, and the half-life of the drug for the differ-
ent formulations was estimated (Table 1). We would like to note,
however, that a good ﬁt of data to a particular model is not neces-
sarily a conﬁrmation that the physical models underlying the
mathematical equation represent the mechanism of release for a
particular formulation, especially if the detailed complete release
proﬁle is unavailable [29].
Regression analysis indicated that the data obtained for the
solution formulation best ﬁts the Higuchi diffusion model: r% = kH-
t½ where r% is the percentage of drug released at time t and kH is
the Higuchi rate constant. In comparison, data from the liposomal
formulation best ﬁt the zero-order kinetic equation: r% = kt. For the
mixture formulation, no single mathematical function was able to
describe the proﬁles across all the methodologies used, and it was
excluded from the half-life calculations. The half-lives calculated
generally showed that the Calu-3 epithelial cell model measured
the longest half-life, followed by dialysis membrane diffusion, iso-
lated perfused lung and ﬁnally in vivo mice lung. An exception to
this order is the relative rates of transport of ciproﬂoxacin from
the liposomal formulation in the IPL and in vivo mice lung.4. Discussion
The transport proﬁles of ciproﬂoxacin from the different cipro-
ﬂoxacin formulations were assessed using three different method-
ologies and were compared to in vivo pharmacokinetic data
reported previously [23]. Qualitatively, the kinetic proﬁles of the
formulations with the different methodologies were similar, and
this was also true for the relative rank of the rates, with the free
ciproﬂoxacin formulation (FCI) having the highest rate of transport,
followed by the mixture formulation and ﬁnally the liposomal cip-
roﬂoxacin formulation (CFI) across all methodologies. Unfortu-
nately, while this rank order remained consistent across all
methodologies, variations in the rates and extent of transport/dif-
fusion were observed between them.
Ciproﬂoxacin was trapped in liposomes by encapsulation of the
drug in an ionised state [24]. The slow transport rates of ciproﬂox-
acin after administration to the in vitro models were consistent
with retention of the liposomes in the donor compartment and
the slow release of ciproﬂoxacin as only uncharged molecules mi-
grated across the liposomal membrane bilayer. All methods used
could be approximated by a zero-order rate kinetic of the liposo-
mal sustained release formulation in contrast to the solution for-
mulation, which was consistent with Higuchi kinetics (which
itself is a good approximation to the planar diffusion equation
solution at short times [29,30]). The Higuchi model is indicative
of a diffusion-controlled transport process, i.e., fully-dissolved cip-
roﬂoxacin diffusing rapidly across the dialysis membrane, or in
case of Calu-3 and IPL models spreading laterally over the mucosal
surface then diffusing across the lung epithelium [20]. Hence, as
concentration in the donor compartment reduces (i.e. in the epi-
thelial lining ﬂuid or inside of the dialysis bag), a reduction inthe rate of diffusion across the membrane or epithelium occurs.
In comparison, the slow rate of transport/diffusion of ciproﬂoxacin
in the liposomal formulation indicates that a constant rate of re-
lease of drug from the liposomes is likely the limiting step (i.e.
slower than the rate of diffusion through the membranes), result-
ing in an apparent zero-order process.
The rationale behind the mixture formulation approach was to
rapidly expose the lung to therapeutic levels of antibiotic, via the
free component, while prolonging residence time through the lipo-
somal component. This approach of combining the immediately
available free ciproﬂoxacin and the slow release liposomal cipro-
ﬂoxacin could be tailored to optimise therapeutic efﬁcacy, reduce
frequency of administration and reduce the potential for formation
of resistant colonies. Interestingly, the rate and extent of ciproﬂox-
acin transported across the Calu-3 cell line and dialysis membrane
was not the predicted mean of the proﬁles for the individual for-
mulations, and none of the four mathematical models could be em-
ployed universally to describe the kinetic proﬁle. This may be
attributed to the dual release components of the formulation,
where the initial phase is a rapid release from the free component,
followed by the contribution of the sustained release of ciproﬂox-
acin from liposomes.
If the mixture formulation followed a dual release proﬁle, a
combination formula Ct = 50%(kt) + 50%(kHt½) based on the best-
ﬁt models for the free and liposomal ciproﬂoxacin formulations
would predict its release proﬁle. The observed values fell below
the predicted values in all test methods, but to different extents.
When the experimental data were compared to predicted values
using normalised root mean square deviation (NRMSD), the ob-
served values in the IPL model were closest to the predicted values
(NRMSD = 0.20), followed by the Calu-3 cell model, the dialysis
technique with NRMSD of 0.92 and 1.13, respectively. This sug-
gests that the in vitro models exhibit an artefact not seen in the
ex vivo model and in vivo studies, i.e., that the presence of lipo-
somes is affecting both the overall transport extent and the rate
in the in vitro models either by interaction of liposomes with the
dialysis membrane/epithelium, with the free drug or both. Further-
more, it should be pointed out that while liposomal formulation
shows no drug release on storage [31], when administered to ani-
mals or humans, it leads to an apparent elimination half-life of 10–
12 h [4,31]. The differences observed in the models may possibly
be dependent on the proximity between the liposomes and the free
drug and the duration of the experiments. The ex vivo model has a
larger surface area for drug absorption compared to the in vitro
models where the free drug will be at a higher concentration and
in closer proximity to the liposomes. Additionally, the longer
experimental duration of the in vitro models could have provided
additional time for any interactions to occur.
Many studies [32–35] that attempted to establish a correlation
between a cell culture system with either an IPL model or in vivo
animal studies have used the apparent permeability of the drugs
(estimated from ﬂux data), together with the apparent ﬁrst-order
absorption rate constant to establish a relationship. However, in
this study, the use of the TSI to deposit aerosol droplets onto the
Calu-3 cells instead of the conventional direct application of drug
Fig. 4. Retention of 14C-ciproﬂoxacin in the lungs of Balb/C mice post-intranasal
instillation of 50 lL of ciproﬂoxacin 1 mg/mL. The lungs of the mice were harvested
following sacriﬁce and processed for liquid scintillation counting to quantify the
amount of ciproﬂoxacin remaining in the lungs. Reproduced with permission from
Respiratory Drug Delivery [23].
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initial concentration of drug deposited, which is required for the
estimation of apparent permeability. This is due to the lack of
information regarding the exact volume of surface liquid produced
by the air interface Calu-3 cells and the volume of aerosol droplets
deposited on the cells. Hence, half-lives for the transport of the for-
mulations based on best-ﬁt kinetic model were used to allow di-
rect comparison of the different formulations and methodologies.
Liposomal and solution formulations displayed a decreasing
absorptive half-life rank order where Calu-3 epithelial model >
dialysis method > IPL model > in vivo mice lung (with the excep-
tion for the liposomal formulation murine lung half-life being
greater than that of the IPL model) (Table 1). The absorptive half-
life of the liposomal formulation in the IPL study was comparable
with the in vivo study in mice, which could be attributed to the
preservation of the organ’s architecture and full range of cell types
that are present in vivo. This includes the presence of transporter
proteins such as P-glycoprotein, multidrug resistance associated
protein and solute carrier transporters in the lung epithelia cells
that may be absent in cell culture models. These transporters
may have an impact on the absorption of ciproﬂoxacin, as trans-
port of this drug has been shown to be mediated by some of these
transporters [36–38]. However, limitation to the IPL technique is
that it is labour-intensive, requires adept technical expertise for
the surgery and perfusion and the limited viability of the lung
ex vivo.
Particularly, when assessing controlled release formulations,
the information obtained from a partial release proﬁle experimen-
tal period may be misleading. Controlled release formulations of-
ten exhibit two distinct phases: the initial rapid release of drug
due to a burst effect followed by a slower drug release correspond-
ing to the sustained drug release phase. Hence, the initial burst ef-
fect may explain the lower absorptive half-life estimated for the
liposomal formulation in the IPL method compared to the in vivo
study, which was carried out over 24 h. This burst effect was ob-
served in the in vivo study (Fig. 4) whereby estimation of the
half-life from the initial two time points showed comparable
half-life (129 min) to the IPL study. Although the IPL model may
not be suitable for the study of controlled release formulations
and its kinetic properties, nevertheless, it provided a good approx-
imation of the absorption half-life for conventional formulations,
as seen with the solution formulation.
The kinetic proﬁles of the different ciproﬂoxacin formulations
observed in the Calu-3 model were in qualitative agreement with
the other methodologies. However, the absorptive half-lives for
both formulations calculated in the Calu-3 model were approxi-
mately an order of magnitude higher compared to that measured
in vivo. The deposition of the ciproﬂoxacin formulation on a rela-
tively small surface area of the Calu-3 cell model could contribute
to the slower transport in comparison with deposition on the lar-
ger surface area available in the lungs. Another contributing factor
could be the lower permeability of ciproﬂoxacin in the Calu-3 cell
model compared to native epithelium. The barrier provided by
Calu-3 cells is greater than that of excised human tissues, rat lungs
and rabbit airway epithelium [32,39]. Calu-3 cell-derived data
have indicated that 2% of insulin would be systemically absorbed
which was lower in comparison with the 5–10% of insulin ab-
sorbed with 6% bioavailability reported in human and rat, respec-
tively [40,41]. It should be noted that bioavailability reﬂects all the
disposition mechanisms (release, absorption, distribution, metabo-
lism, phagocytosis, mucociliary clearance) that affect encapsulated
and unencapsulated drug [10,42] and is not equivalent to the per
cent absorbed.
However, the simplicity, robustness and experimental control
available with the air interface Calu-3 model provide a good plat-
form for assessing the initial kinetic proﬁle of controlled releaseformulations (e.g. rank-order correlations). And may be better than
‘‘tissue’’ models for identifying individual processes that involve
complex and dynamic relationships across different cell types [22].
5. Conclusions
Liposomal formulation of ciproﬂoxacin has the potential to pro-
vide a promising new treatment for pulmonary infections. The re-
lease of drug from the liposomal formulation was compared to
release from a solution formulation in a series of biopharmaceuti-
cal models for inhaled drug delivery. The same rank order and a
consistent mechanism of drug release/transport (concentration-
independent for the liposomal formulation, diffusion controlled
for the solution formulation) were discerned for the formulations
using the in vitro andex vivo methods, and this was predictive of
the proﬁles in vivo. The use of complimentary in vitro methodolo-
gies provided a robust analysis of formulation behaviour and pre-
dicted the in vivo pharmacokinetics. The liposomal formulation
provided zero-order release kinetics that prolonged antibiotic res-
idence time in the lungs.
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